Citations

Institution: Mayo Clinic Clear

Showing 10 of 108119 citations.

Characteristics of Patients and Prognostic Factors Across Treatment Lines in Metastatic Colorectal Cancer: An Analysis From the Aide et Recherche en Cancérologie Digestive Database
Bachet, Jean‐Baptiste , Gramont, Aimery de , Raeisi, Morteza , Rakez, Manel , Goldberg, Richard M. , Tebbutt, Niall C. , Cutsem, Eric Van , Haller, Daniel G. , Hecht, J. Randolph , Mayer, R., Benson, Al B. , Sobrero, Alberto F. , Adams, Richard , Grothey, Axel, Chibaudel, Benoist , De Gramont, Aimery , Van Cutsem, Eric , Lichtman, Stuart M , Benson, Al , Sobrero, Alberto , Tabernero, Josep , Adams, Richard , Yoshino, Takayuki , André, Thierry , Shi, Qian , Chibaudel, Benoist , Tebbutt, Niall C , Mayer, Robert J., Lichtman, Stuart M. , Tabernero, Josep , Zalcberg, John , Yoshino, Takayuki , André, Thierry , Shi, Qian

Journal of Clinical Oncology | May 5, 2025 | Volume: 43 | Issue: 18 | Pages: 2094-2106

10.1200/jco-24-01968 | PMID 40324123 Get It

PURPOSE Several lines of treatment can be used sequentially in patients with metastatic colorectal cancer. We investigated the evolution of patient/tumor characteristics and their prognostic impact across treatment lines to develop an overall prognostic score (OPS). PATIENTS AND METHODS Individual patient data from 48 randomized trials were analyzed. The end point was overall survival (from random assignment to death). Missing data were imputed. The complete data set was then separated into construction (80%) and validation sets (20%). The Cox's model was used to define risk groups for survival using the OPS. The discrimination capability was assessed in each treatment-line via bootstrapping to obtain optimism-corrected calibration and discrimination C-indices. Internal validation was done in the validation set. RESULTS A total of 37,560 patients (26,974 in first-line [1L], 7,693 in second-line [2L], and 2,893 in third-line [3L]) were analyzed. Some clinical, biological, and molecular characteristics of patients/tumors included in therapeutic trials evolve over the lines. Seven independent prognostic variables were retained in the final multivariate model common to all lines: Eastern Cooperative Oncology Group performance status, hemoglobin, platelet count, WBC/absolute neutrophil count ratio, lactate dehydrogenase, alkaline phosphatase, and the number of metastatic sites. The OPS was used to define four patient subgroups with significantly different prognoses in 1L, 2L, and 3L, separately, with adequate C-indices: 0.65, 0.66, and 0.69 in the construction set and 0.65, 0.66, and 0.68 in the validation set, respectively. The OPS was not predictive, with 3L drugs ( v placebo) or subsequent line (2L/1L or 3L/2L) extending survival in all prognostic groups. CONCLUSION The same prognostic model using practical variables can be used before all treatment lines. The OPS could better stratify patients in future clinical trials and help to therapeutic decision in routine practice.
Long-term Effects of Concomitant Lateral Meniscal Management on ACL Reconstruction Revision Rate and Secondary Meniscal and Cartilaginous Injuries
Wållgren, Jonas Olsson , Oeding, Jacob F. , Musahl, Volker , Olsson Wållgren, Jonas , Oeding, Jacob F , Kaarre, Janina , Senorski, Eric Hamrin , Samuelsson, Kristian

Orthopaedic Journal of Sports Medicine | May 5, 2025 | Volume: 13 | Issue: 5 | Pages: No page available

10.1177/23259671251330655 | PMID 40342353 Get It

Background: When injuring the anterior cruciate ligament (ACL), simultaneous meniscal tears often occur. However, little data describe ACL reconstruction (ACLR) and the subsequent risk of revision ACLR, as well as cartilaginous and meniscal damage after primary ACLR with different treatments for injury of the lateral meniscus (LM). Purpose: To investigate (1) how different LM treatments during primary ACLR affect the odds of revision ACLR and the cartilaginous and meniscal status at revision in a long-term follow-up and (2) whether the increased risk of subsequent meniscal and cartilaginous injuries seen with meniscal resection in the short term would continue in the long term, and (3) the increased risk with subsequent meniscal injuries with meniscal repair. Study Design: Cohort study; Level of evidence, 3. Methods: Data from the Swedish National Knee Ligament Registry were used. The study compared 2 groups: patients with isolated ACLR and patients with ACLR and concomitant LM injury, further subdividing the latter into 4 treatment types: repair, resection, both, and left in situ. Patients with medial meniscal injuries were excluded. The main outcomes studied were the odds for revision ACLR and the cartilaginous and meniscal status at revision 5 and 10 years after primary surgery. Results: Data for 5 years were available for 22,208 patients and data for 10 years were available for 11,058 patients. Compared with isolated ACLR, patients with concomitant LM injury left in situ had higher odds of revision ACLR at both 5 years (odds ratio [OR], 1.49; 95% CI, 1.14-1.95; P = .004) and 10 years (OR, 1.55; 95% CI, 1.09-2.19; P = .01), while those with LM repair had higher odds at 5 years (OR, 1.73; 95% CI, 1.23-2.43; P = .002). LM repair also increased the odds of subsequent meniscal injuries at 5 years (OR, 3.52; 95% CI, 1.76-7.03; P = .0004) and 10 years (OR, 7.26; 95% CI, 1.67-31.52; P = .008). Partial meniscectomy did not show an increased risk of cartilage injury, subsequent meniscal injury, or revision ACLR at long-term follow-up compared with the control group. Conclusion: This demonstrates that over 5 and 10 years, LM repair during primary ACLR is associated with an increased risk of revision ACLR and subsequent meniscal injuries. The higher risk of revision ACLR when the LM is left in situ emphasizes the need for careful consideration of treatment methods. Conversely, partial meniscectomy did not show an associated increased risk of cartilaginous injury in the long term and is associated with a lower risk of subsequent meniscal injury and revision ACLR than other treatment options, raising questions about whether preserving the meniscus at all costs is always the best approach.
3D Printed Hollow Microneedles for Dermal and Transdermal Drug Delivery: Design, Fabrication, Application, and Perspective
Ghaznavi, Amirreza , Alavi, Sonia , Hara, Seth A. , Gemeinhart, Richard A. , Xu, Jie , Gemeinhart, Richard A , Xu, Jie , Lin, Yang

Molecular Pharmaceutics | May 5, 2025 | Volume: 22 | Issue: 6 | Pages: 2747-2764

10.1021/acs.molpharmaceut.4c01261 | PMID 40323438 Get It

Extracorporeal membrane oxygenation support: palliative care integration – patient experience and quality of life
Highet, Bridget H. , Cushenbery, Kristin, Sarangi, Swapna , Jena, Anek , Banker, Himanshi , Kilpatrick, Molly, Robinson, Maisha T. , Robinson, Maisha, Guru, Pramod

BMJ Supportive & Palliative Care | May 5, 2025 | Volume: 15 | Issue: 6 | Pages: 818-821

10.1136/spcare-2025-005503 | PMID 40324841 Get It

Objective The pattern and timing of palliative care utilisation and end-of-life characteristics in extracorporeal membrane oxygenation (ECMO)-supported patients remain underused. We wanted to share our centre’s experience. Methods This is an institutional review board-approved retrospective study of 45 patients who underwent ECMO at a large ECMO centre in North America between January 2013 and July 2018. Results Only 28.9% of the ECMO patients received in-hospital palliative care consultation at a median of 18 days (IQR 12–31) after hospitalisation and 10.5 days (IQR 1–28) from ECMO initiation. 1-year mortality was high, with 44% dying during hospitalisation and an additional 13% within the following year. Patients experienced prolonged hospitalisations (median hospital length of stay: 39 days, IQR 19–89) and exhibited high rates of tracheostomy (53%) and renal replacement therapy (60%). Most end-of-life cases involved the withdrawal of life-sustaining therapy during ECMO, yet only 53% had a completed living will. Conclusion Our study underscores the need for early initiation of palliative care consultation to enhance symptom management, advance care planning, caregiver support and quality of life for ECMO patients and their families.
The evolving therapeutic revolution in adult acute lymphoblastic leukemia
Kantarjian, Hagop M. , Litzow, Mark R. , Luger, Selina M. , Ribera, Josep‐María , Short, Nicholas J. , Chifotides, Helen T. , Jabbour, Elias , Kantarjian, Hagop , Papayannidis, Cristina , Ribera, Josep-Maria , Short, Nicholas , Chifotides, Helen T , Jabbour, Elias , Jain, Nitin , Papayannidis, Cristina

Cancer | May 5, 2025 | Volume: 131 | Issue: 10 | Pages: No page available

10.1002/cncr.35872 | PMID 40323723 Get It

Abstract The past decade has witnessed remarkable advances in deciphering the pathophysiology of acute lymphoblastic leukemia (ALL) and in developing novel targeted therapies. Basic research and genomic mapping have identified new prognostic biomarkers, targets, and ALL subtypes (e.g., Philadelphia‐like ALL). The ongoing therapeutic revolution in ALL is driven by the addition to the treatment arsenal of therapies that target the ABL fusions, like the BCR::ABL1 tyrosine kinase inhibitors, as well as novel agents that target CD19 and CD22: the CD22 antibody–drug conjugate inotuzumab ozogamicin, the bispecific CD3/CD19 T‐cell engager antibody blinatumomab, and CD19 chimeric antigen receptor T‐cell therapies. These combinations have improved the long‐term survival rates in B‐cell ALL to 70%, and in Philadelphia chromosome‐positive ALL to 80%–90%. The desired goals are to achieve cure rates comparable to those in pediatric ALL and to reduce or eliminate the need for prolonged intensive/maintenance chemotherapy and associated toxicities.
A Quarterly Multidisciplinary Craniofacial Operative Team Conference to Improve Surgical Outcomes and Adherence to Clinical Pathways: Does it Work?
Grove, Austin M. , Kirsch, Hannah M., Hanley, Seth P., Bristol, Ruth E., Kurnik, Nicole M. , Singh, Davinder J. , Singh, Davinder J , Grove, Austin , Sitzman, Thomas J.

Journal of Craniofacial Surgery | May 5, 2025 | Volume: 36 | Issue: 7 | Pages: 2306-2310

10.1097/scs.0000000000011468 | PMID 40323582 Get It

Craniofacial surgery requires a multidisciplinary care approach in the perioperative period. In an effort to guide clinical decision making and standardize care, many institutions have implemented craniofacial surgical pathways, describing numerous variables to monitor and specific actions that must be completed by each involved discipline in the perioperative period. Adherence to these pathways can be challenging given the complexity of the protocol and the multiple disciplines involved. In an effort to improve adherence to our institution’s perioperative pathway, the authors implemented a quarterly, multidisciplinary craniofacial operative team meeting to review the pathway and improve the quality of care. The authors report results from a retrospective review of craniosynostosis suturectomy operations at a single site in the 2 years before and 2 years after the start of our team meeting to review perioperative care. A total of 141 operations were included (70 before the meeting and 71 after). Perioperative outcomes and adherence to our surgical pathway were compared. Following the start of our team meetings, there was a significant decrease in the time under anesthesia, patients requiring blood transfusion, and total hospital length of stay ( P <0.05). There was also improved adherence to the craniofacial pathway, with significantly more operations applying peripheral nerve blocks to all locations specified in our pathway with the proper drug contents ( P <0.05). Our findings suggest that craniofacial operative team meetings with a goal of reviewing the surgical pathway and discussing improvements in care plans with all involved providers can significantly improve adherence to operative pathways and surgical outcomes.
Impact of Digital Navigation on Screening Adherence With the Multi-Target Stool DNA Test
Greene, Mallik , Pew, Timo, Fendrick, A. Mark, Ozbay, A. Burak , Kisiel, John B. , Fendrick, A. Mark , Limburg, Paul J.

Journal of Health Economics and Outcomes Research | May 5, 2025 | Volume: 12 | Issue: 1 | Pages: No page available

10.36469/001c.133939 | PMID 40336760 Get It

Background Colorectal cancer (CRC) is the fourth most frequently diagnosed cancer and the second leading cause of cancer-related deaths in the United States. Screening can prevent CRC by detecting advanced precancerous lesions. Adherence to screening is crucial in reducing CRC disease burden; however, there is limited research on the impact of digital outreach screening uptake and adherence. Objective This study evaluated the impact of different digital outreach channels on patient adherence to CRC screening with a multi-target stool DNA (mt-sDNA) test in a real-world setting. Methods Patients were individuals aged 45 to 85 years with a valid mt-sDNA test order from Exact Sciences Laboratories, LLC (Jan. 1, 2023–Sept. 23, 2023). All patients received letters and phone calls; some received short message service (SMS), email, or both. Adherence and time to test return were compared across digital outreach categories stratified by patient characteristics. Multivariable regression evaluated the association of digital outreach methods with adherence and time to test return. Results Among 2 425 308 patients (43.5% between 50 and 64 years, 58.2% female), digital SMS only (62.7%) was the most common outreach method. Overall adherence was 70.1%, with highest adherence in the digital SMS-plus-email group (72.9%). Mean time to test return from shipment of mt-sDNA kit to receipt of valid test was 25.8 days. In adjusted analyses, patients receiving digital SMS plus email had the highest odds of test return (odds ratio, 1.75; 95% confidence interval [CI], 1.73-1.78; P <.001) and had return times 8.7% shorter than the no-digital-outreach group (95% CI, 8.2-9.2; P <.001). Discussion Among nationally insured individuals within the recommended age range for CRC screening, overall adherence to the mt-sDNA test was in the 70s, with the highest rates in the digital (SMS and email) outreach group and the lowest in the no-digital-outreach group. Conclusions These findings highlight the importance of multichannel navigation in facilitating completion of CRC screening with the mt-sDNA test.
Nonhormonal Treatment of Menopausal Vasomotor Symptoms
Huang, Alison J. , Grady, Deborah, Faubion, Stephanie, Faubion, Stephanie S.

JAMA Internal Medicine | May 5, 2025 | Volume: 185 | Issue: 7 | Pages: 874

10.1001/jamainternmed.2025.0990 | PMID 40323611 Get It

This work discusses nonhormonal treatment of menopausal vasomotor symptoms.